
USD
+$0.00
(+0.00%
)At Close (As of Dec 11, 2025)
$3.12B
Market Cap
68.56
P/E Ratio
0.36
EPS
$35.70
52 Week High
$16.10
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $664M |
| Total Revenue | $781M |
| Cost Of Revenue | $118M |
| Costof Goods And Services Sold | $118M |
| Operating Income | -$165M |
| Selling General And Administrative | $418M |
| Research And Development | $328M |
| Operating Expenses | $829M |
| Investment Income Net | - |
| Net Interest Income | -$28M |
| Interest Income | $13M |
| Interest Expense | $40M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.8M |
| Income Before Tax | -$197M |
| Income Tax Expense | $1.2M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$198M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$156M |
| Ebitda | -$155M |
| Net Income | -$198M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $664M |
| Total Revenue | $781M |
| Cost Of Revenue | $118M |
| Costof Goods And Services Sold | $118M |
| Operating Income | -$165M |
| Selling General And Administrative | $418M |
| Research And Development | $328M |
| Operating Expenses | $829M |
| Investment Income Net | - |
| Net Interest Income | -$28M |
| Interest Income | $13M |
| Interest Expense | $40M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.8M |
| Income Before Tax | -$197M |
| Income Tax Expense | $1.2M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$198M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$156M |
| Ebitda | -$155M |
| Net Income | -$198M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Apellis Pharmaceuticals, Inc. is an innovative clinical-stage biopharmaceutical company located in Waltham, Massachusetts, specializing in the development of groundbreaking therapies that target the complement system for the treatment of autoimmune and inflammatory diseases. With a robust pipeline, including its flagship investigational asset, the company aims to transform treatment paradigms for patients suffering from complex conditions marked by unmet medical needs. Committed to advancing the science of complement inhibition, Apellis is poised to play a pivotal role in reshaping the biopharmaceutical landscape and delivering impactful solutions to healthcare challenges.